Here is the link to that discussion.
KK mentions challenges Cynata has encountered with the trial, including the location of the trial centers vs where the patients are located and what steps Cynata has undertaken to overcome that (34:54 mins onwards).
He also addressed an issue of patients with DFU - the lack of getting proper care. Given that as a result of this trial all groups, including the control grou, have access to adequate care, and therefore show an improvement compared to the "real-world", albeit not dramatic and by itself won't solve the problem.
On a side note, there is an additional Research Program currently underway at Monashm, comparing MSCs from different sources:
https://www.monash.edu/__data/assets/pdf_file/0006/3360084/SRP-23-24-Margeaux-Hodgson-Garms.pdf
Here is the link to that discussion.KK mentions challenges...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $36.15M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 11278 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.0¢ | 5779 | 1 |
View Market Depth
| Last trade - 08.59am 24/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |
Day chart unavailable